$23.76
▲ +0.5% Today
as of Jul 22, 16:48 ET
Last 30 days
Recent Press Releases & News
Is Denali Therapeutics (DNLI) Overvalued After Its FDA Approval?
Deutsche Bank Adjusts Price Target on Denali Therapeutics to $35 From $31, Maintains Buy Rating
Will Recent Setbacks Impact Growth Prospects of DNLI Stock?
Overview
52-week range
$13
$24
100% of range
Avg surprise (last 3)
-0.6%
Avg reaction (last 2)
-8.0%
0% positive
Latest IV / EM
68%
EM ±15.5% · $23 · Aug 21
Earnings trends
EPS — actual vs estimate
Actual Estimate
Revenue vs Net Income
Revenue Net income
Earnings history
| Date | Period | Actual EPS | Est | Surprise | YoY %Δ | Day react | Source |
|---|---|---|---|---|---|---|---|
| Thu May 7, 2026 | Mar/2026 | $-0.69 | $-0.73 | +5.5% | +11.5% | -3.4% | earnings |
| Tue Sep 30, 2025 | Sep 2025 | $-0.74 | — | — | — | — | financials |
| Mon Aug 11, 2025 | Jun/2025 | $-0.72 | $-0.74 | +2.7% | — | — | earnings |
| Tue May 6, 2025 | Mar/2025 | $-0.78 | $-0.71 | -9.9% | — | -12.6% | earnings |
| Mon Sep 30, 2024 | Sep 2024 | $-0.63 | — | — | — | — | financials |
| Sun Jun 30, 2024 | Jun 2024 | $-0.59 | — | — | — | — | financials |
| Sun Mar 31, 2024 | Mar 2024 | $-0.68 | — | — | — | — | financials |
| Sat Sep 30, 2023 | Sep 2023 | $-0.72 | — | — | — | — | financials |
| Fri Jun 30, 2023 | Jun 2023 | $1.30 | — | — | — | — | financials |
Upcoming
| Date | Fiscal | Time | EPS Est | LY EPS | YoY %Δ |
|---|---|---|---|---|---|
| Mon Aug 10, 2026 | Jun/2026 | OTHER | -$0.72 | -$0.72 | 0.0% |
Financials
Income statement (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Revenue | — | — | — | — | — | — | — | — |
| Cost of revenue | — | — | — | — | — | — | — | — |
| Gross profit | — | — | — | — | — | — | — | — |
| Operating income | $-137M | — | $-137M | $-135M | $-146M | — | $-123M | $-117M |
| Net income | $-128M | — | $-127M | $-124M | $-133M | — | $-107M | $-99M |
| EPS (diluted) | $-0.69 | — | $-0.74 | $-0.72 | $-0.78 | — | $-0.63 | $-0.59 |
Balance sheet (quarterly)
| Metric | Mar 2026 | Dec 2025 | Sep 2025 | Jun 2025 | Mar 2025 | Dec 2024 | Sep 2024 | Jun 2024 |
|---|---|---|---|---|---|---|---|---|
| Cash & equivalents | $388M | $205M | $91M | $141M | $57M | $175M | $91M | $75M |
| Inventory | — | — | — | — | — | — | — | — |
| Total current assets | $1.02B | $901M | $883M | $935M | $879M | $864M | $869M | $928M |
| Total assets | $1.27B | $1.14B | $1.06B | $1.17B | $1.27B | $1.37B | $1.45B | $1.50B |
| Long-term debt | — | — | — | — | — | — | — | — |
| Total liabilities | $340M | $131M | $129M | $139M | $149M | $144M | $136M | $116M |
| Total equity | $926M | $1.01B | $926M | $1.03B | $1.12B | $1.23B | $1.32B | $1.39B |